Spiderwort’s 2023 Year in Review: Advancing Innovation in Regenerative Medicine
As 2023 comes to a close, we look back at the progress and advancement we’ve made to push the boundaries of regenerative medicine through our continued investment in cellulose-based biomaterial research and development.
Both of our product lines — CelluBridge and CelluJuve — reached new heights as we drove forward with our mission to revolutionize treatments for acute spinal cord injuries and redefine standards in the medical aesthetics industry.
Expansion and Growth: Joining Elite Programs and Accelerators
Our journey this year was marked by new growth and increased visibility in the industry.
Spiderwort was honoured to be accepted into the MaRS Health Science Portfolio and the elite CELS Valley Ready Program. These inclusions not only validate our scientific advancements but also open doors to invaluable resources and networks. Moreover, graduating from Invest Ottawa’s Accelerator Program to the Scale-Up program marked our transition from a promising young start-up to a defined company ready for global impact.
Award-Winning Innovation: Earning Prestigious Accolades
This year we were fortunate to receive industry validation through countless meetings and updates with industry experts, medical professionals, and investors.
A momentum-building achievement early in the year included winning the Judge’s Choice Award at the Octane Medical Aesthetics Tech Forum. This recognition is a testament to the innovative work we are doing with our CelluJuve technology — with ongoing research suggesting an improvement to dermal filler durability and longevity. The work we’re doing in this field hopes to bring a new alternative to legacy filler treatments used today.
In May, the team was honoured to have been recognized with the SME of the Year award by Regroupement des gens d’affaires de la Capitale nationale (RGA).
Global Outreach: Spiderwort’s Industry Presence and European Tour
Our commitment to global outreach was evident in a very busy, but incredibly rewarding industry events schedule, including a successful European Tour where we engaged and shared our approach and vision with key leaders in the field.
Additionally, our presence at major industry events across the US, Europe and Canada such as BIO 2023, BIO Europe, MedTech Conference, Biotech Showcase, Global Aesthetics Conference, Octane Aesthetics, among others, allowed us to connect with medical professionals, patients, influencers, peers, and investors, solidifying our position and profile in the biotech landscape.
As we reflect on a year filled with innovation and growth, we are more committed than ever to our mission and look forward to sharing more in 2024.
We’re grateful for the inspiring work of our staff and extend a special thank you to our partners and supporters who have helped make the growth we experienced this year a reality.